Lilly’s revenue soars 48%, driven by demand for its GLP-1s
MarketWatchPaywall
Read Full Article at MarketWatch →Ad Slot — In-Article (728x90)
Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
This is a summary. For the full story, read the original article at MarketWatch.
Original source: MarketWatch